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Abstract: Hyponatremia is especially common in older people. Recent evidence highlights 
that even mild, chronic hyponatremia can lead to cognitive impairment, falls and fractures, 
the latter being in part due to bone demineralization and reduced bone quality. 
Hyponatremia is therefore of special significance in frail older people. Management of 
hyponatremia in elderly individuals is particularly challenging. The underlying cause is 
often multi-factorial, a clear history may be difficult to obtain and clinical examination is 
unreliable. Established treatment modalities are often ineffective and carry considerable 
risks, especially if the diagnosis of underlying causes is incorrect. Nevertheless, there is 
some evidence that correction of hyponatremia can improve cognitive performance and 
postural balance, potentially minimizing the risk of falls and fractures. Oral vasopressin 
receptor antagonists (vaptans) are a promising innovation, but evidence of their safety and 
effect on important clinical outcomes in frail elderly individuals is limited. 
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1. Introduction 
Hyponatremia is the commonest electrolyte imbalance encountered in clinical practice [1]. It is 
associated with multiple poor clinical outcomes including increased mortality [2], increased length of 
hospital stay [3,4] and institutionalization [4]. Hyponatremia occurs due to disruption of sodium and 
water homeostasis, normally maintained by complex multi-system physiological mechanisms [5].  
It represents an excess of water relative to sodium, though both sodium and total body water may be 
increased, normal or diminished. Consequently, there are numerous potential underlying causes of 
hyponatremia, spanning a broad spectrum of diseases, pharmacotherapy and pathophysiological variants 
each with different treatment requirements. This review examines some of the recent insights into the 
special implications of hyponatremia in the older patient, paying particular attention to the potential for 
even mild, chronic hyponatremia to result in subtle symptoms such as cognitive impairment, bone 
demineralization, falls and fractures [6–8]. The unique challenges of accurate diagnosis and treatment 
of the underlying causes in the older patient are also highlighted. 
2. Epidemiology 
Prevalence of hyponatremia is known to increase in frail patient groups, particularly elderly patients 
where hyponatremia is observed in almost half of acute geriatric admissions [9,10]. Older people have 
an increased predisposition to hyponatremia due to degenerate physiology, multiple co-morbidities and 
polypharmacy [5]. Hospitalized older people have a further susceptibility to hyponatremia due to 
dehydration, inappropriate fluid therapy and iatrogenic interventions. 
Hyponatremia in elderly patients is predominantly mild and chronic (i.e., serum sodium  
130–134 mmol/L developing over >48 h) [11]. These cases are classically devoid of the obvious 
neurological symptoms seen in acute severe hyponatremia due to homeostatic compensatory 
mechanisms which allow brain cells to adapt to changes in plasma osmolality within hours. As a result, 
mild, chronic hyponatremia has typically been considered to be asymptomatic despite being associated 
with major geriatric presentations (e.g., falls and confusion), and multi-organ pathological changes. 
Also, in the absence of obvious neurological symptoms, mild, chronic hyponatremia is at risk of being 
overlooked. The older person’s increased risk of both hyponatremia and its subsequent clinical 
sequelae makes hyponatremia in elderly patients of particular clinical importance. 
3. Does Hyponatremia Cause Cognitive Impairment? 
One of the symptoms often associated with hyponatremia is cognitive impairment, particularly in 
elderly populations. In cases of acute hyponatremia, the pathological mechanisms involved are well 
understood, with the neurological problems thought to be due to cerebral edema and hyponatremic 
encephalopathy [12]. However, understanding of such mechanisms in the more prevalent, chronic 
hyponatremia is poor. Several studies have recently found an association between cognitive impairment 
and chronic hyponatremia, even at a mild to moderate level. 
In a study examining performance in a battery of cognitive function tests, Renneboog et al. [6] 
found that hyponatremic participants had a median response time of 673 ms across the various 
assessments. Each participant acted as their own control, and when participants were normonatremic, 
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the median response time was found to be significantly reduced at 615 ms (p < 0.001). Similarly, 
Vaghasiya et al. [13] conducted a study evaluating the performance of hyponatremic participants in the 
Mini Mental State Examination (MMSE), with the assessment being repeated again after correction  
of the electrolyte disorder in the same participants. There was an increase in MMSE score following 
improvement in serum sodium concentration in 93% of patients (p = 0.001). As the only aspect of the 
investigations that varied was the serum sodium level, the findings from both of these studies strongly 
suggest that the correction of hyponatremia is the factor causing the improved cognitive performance. 
Although a learning effect cannot be excluded, the MMSE is robust in repeat testing and shows little 
susceptibility to learning effects [14,15]. Moreover, in the study by Renneboog et al. [6], the possibility 
of a learning effect was eliminated as half of the participants tested initially had normal serum sodium 
levels while the remaining participants were tested first during a period of hyponatremia. Therefore, it 
seems likely that hyponatremia itself leads to cognitive impairment, and, additionally, that correction 
of hyponatremia can lead to improved cognition. However, some caution is warranted as the study by 
Renneboog et al. was unblinded and Vaghasiva et al. have not fully published their results. 
Gunathilake et al. [16] used the Audio Recorded Cognitive Screening Tool to compare the 
cognition of hyponatremic participants to a control group. They concluded that the scores of the group 
with mild hyponatremia were on average 4.67 units lower than the control group (p = 0.01, 95% CI 
1.56–7.79). Interestingly, the significant reduction in cognitive performance occurred when sodium 
levels decreased by as little as 5 mmol/L. 
Despite these studies using different methods of assessing cognition, all consistently found that 
cognitive impairment occurs in patients with chronic hyponatremia. However, the mechanisms explaining 
this association remain unclear. In chronic hyponatremia, serum sodium levels decline gradually, 
allowing the body time to adapt. To prevent swelling initially, the glial cells use the Na+-K+-ATPase 
system to move sodium out of cells whilst also expelling osmolytes [17]. This adaptation results in water 
leaving the brain following an osmotic gradient, preventing the accumulation of fluid in cells and thus 
preserving function [18]. Therefore, any cognitive impairment associated with chronic hyponatremia is 
due to a different pathological mechanism than is the case for acute hyponatremia. 
Potentially, much of the cognitive impairment may be secondary to the conditions causing 
hyponatremia. For example, liver cirrhosis is known to be one of the causes of chronic hyponatremia 
and 62% of patients with this condition score lower than expected on psychometric testing, even when 
normonatremic [19]. Further research is needed into the mechanisms by which chronic hyponatremia 
leads to cognitive impairment. 
4. Hyponatremia and Bone Demineralization 
4.1. Non-Randomised Rodent Studies 
Hyponatremia is also reputed to lead to bone demineralization and fractures. Verbalis et al. [8] used 
a rat model of syndrome of inappropriate anti-diuretic hormone (SIADH) to measure bone 
demineralization in six week old male rats compared to a control group of normonatremic rats. Mean 
serum sodium concentration [sNa+] of the hyponatremic and normonatremic groups were 110 ± 2 mmol/L 
and 141 ± 1 mmol/L respectively. Following three months in a hyponatremic state, the rats had a 30% 
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reduction in femoral bone mineral density (BMD) in comparison to the normonatremic rats (p < 0.001). 
Barsony et al. [20] used a similar rodent model as Verbalis et al. [8] but, to replicate the effect in the 
elderly, they used male rats aged 22 months. Fifteen rats were subjected to hyponatremia for 18 weeks 
with a mean [sNa+] of 112.7 ± 1.3 mmol/L and 10 rats were used as controls with a mean [sNa+] of 
142.7 ± 1.1 mmol/L. A 16% reduction in BMD was seen in the hyponatremic group (p < 0.05). Thus, 
rodent studies by both Verbalis et al. [8] and Barsony et al. [20] show significant decreases in excised 
femoral BMD resulting from chronic hyponatremia. The two-fold discrepancy in effect between these 
two studies is probably due to the aged control rats in the Barsony et al. [20] study also losing BMD 
through the ageing process.  
4.2. Case-Control Studies 
Several studies have looked at the relationship between hyponatremia and bone fractures. Three 
case-control studies of individuals aged 65 years or over compared the prevalence of hyponatremia 
where the case group had a verified bone fracture and the control group had no history of bone fracture 
(Figure 1). The study by Gankam Kengne et al. [7] determined a prevalence of hyponatremia in the 
case and control groups of 13.1% and 3.9% respectively (p < 0.01) (Figure 1). Two other studies found 
the prevalence of hyponatremia to be 9.1% and 16.9% in the case groups compared with 4.1% and 
4.6% in control groups (p = 0.007 and p = 0.03) [21,22] (Figure 1). 
Figure 1. Prevalence of hyponatremia in patients with a bone fracture (case) and without a 
bone fracture (control). 
 
For the association between hyponatremia and bone fractures, adjusted ORs of 4.16 and 4.80 were 
determined (95% CI: 2.24–7.71 and 1.06–21.67) [7,22]. The first OR was adjusted for possible 
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confounding variables identified through univariate analysis as having p < 0.05 and the other was 
adjusted for age only. 
The results from these case-control studies demonstrate a higher prevalence of hyponatremia in the 
case group than in the control group as well as a strong relationship between hyponatremia and  
bone fractures after adjusting for potential confounding variables. However, deductions about the 
relationship between hyponatremia and osteoporosis cannot be made from these case-control studies 
because they do not provide BMD data. 
4.3. Cross-Sectional Cohort Studies 
Three cross-sectional cohort studies assessed the relationship between hyponatremia and a reduction 
in BMD in humans and all had a mean age greater than 60 years. The study by Verbalis et al. [8] used 
information from the Third National Health and Nutrition Examination Survey. 5598 subjects were 
normonatremic whereas the exact number of individuals who were hyponatremic was not provided. 
Kinsella et al. [23] undertook a cohort study involving 1408 females. There were 254 verified fractures 
and 4.2% (59 individuals) were hyponatremic. Of the subjects with a fracture, 8.7% were hyponatremic 
whereas only 3.2% without a fracture were hyponatremic. The study by Hoorn et al. [24] involved 5208 
patients, of which 7.7% (399 individuals) had hyponatremia. 
Verbalis et al. [8] demonstrated a significant positive linear relationship between femoral BMD and 
[sNa+] in the hyponatremic subjects (p < 0.01) whereas no relationship was seen in the normonatremic 
individuals (p = 0.99). This correlation was further established as the ORs for hyponatremia and 
osteoporosis at the femoral neck and total hip (defined by BMD with T-score < −2.5) were 2.87 and 
2.85 (95% CI: 1.41–5.81 and 1.03–7.86). These results substantiate an association between hyponatremia 
and osteoporosis. An association between hyponatremia and osteoporosis was also demonstrated in the 
study by Kinsella et al. [23]. They reported a significant decrease in BMD in the hyponatremic 
subjects when compared to the normonatremic subjects, with mean T-scores of −2.6 and −2.3 (p = 0.03) 
respectively. Hyponatremic individuals also had a significantly higher prevalence of osteoporosis  
of 57.6% compared with 44.3% in controls (p = 0.04). Hoorn et al. [24] did not find a correlation 
between hyponatremia and BMD in either the lower femoral neck or the lumbar spine after adjustment 
for age and sex (p = 0.105 and p = 0.473). Kinsella et al. [23] established a fully adjusted OR for the 
relationship between hyponatremia and bone fractures of 2.25 (95% CI: 1.24–4.09) (details of adjusted 
factors are shown in Table 1). As this was adjusted for T-score, this shows that the increased risk of 
bone fractures caused by hyponatremia occurs independently of BMD. 
Hoorn et al. [24] established a fully adjusted OR of 1.61 for the association between hyponatremia 
and vertebral fractures (95% CI: 1.00–2.59). For non-vertebral fractures, an adjusted OR of 1.34 was 
found (95% CI: 1.08–1.68) (adjustments shown in Table 1). Consequently, these results show a 
positive correlation between hyponatremia and both non-vertebral and vertebral fractures. 
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Table 1. Factors adjusted for in models in the cohort studies. 
Study Adjustments 
Verbalis et al. (2010) [8] age (years), sex, body mass index, history of diuretic use, physical 
activity, serum 25-hydroxy-vitamin D levels 
Kinsella et al. (2010) [23] age (years), T-score, chronic kidney disease stage, osteoporotic risk 
factors (amenorrhoea, low dietary calcium (Ca2+) intake, high alcohol 
intake, maintenance steroids, ever having smoked, family history of 
osteoporosis and history of liver disease) and osteoporosis treatment 
(use of Ca2+, vitamin D, antiresorptive therapy and hormonal 
replacement therapy) 
Hoorn et al. (2011) [24] age (years), sex, body mass index, disability index, use of diuretics or 
psycholeptics, recent falls and prevalent diabetes mellitus 
4.4. Falls 
The work of Renneboog et al. [6] indicates that chronic hyponatremia, even when mild, is related  
to an increased risk of falls. They determined an adjusted OR of 67.43 (95% CI: 7.48–607.42) for the 
relationship between chronic asymptomatic hyponatremia and falling in patients with a mean age of  
72 years. They adjusted for age, sex and an array of other potential confounders determined through 
univariate analysis. Moreover, correction of hyponatremia resulted in improvements in the degree of 
postural sway. 
In summary, human studies have consistently established a relationship between chronic hyponatremia 
and an increased risk of bone fractures. Chronic hyponatremia leads to decreased BMD in young and 
old rats but the effects of chronic hyponatremia on BMD in humans is less clear as studies have 
reported conflicting results. Verbalis et al. [8] and Kinsella et al. [23] established that hyponatremia 
was associated with a reduction in BMD, though Kinsella et al. [23] reported that hyponatremia  
caused bone fractures independently of BMD status. Hoorn et al. [24] found no relationship between 
hyponatremia and BMD. Due to the increased risk of falling with hyponatremia, these patients are at  
a considerably greater risk of sustaining a fracture because of the combined risks of fracture due to 
hyponatremia (either due to a reduction in BMD or bone quality) and increased risk of falling.  
5. Diagnosing the Causes of Hyponatremia 
Clinical management of hyponatremia is based on treating the underlying causes (see Table 2) but 
accurate determination of etiology of hyponatremia is notoriously challenging, particularly in elderly 
patients [25]. The most widely accepted means of obtaining accurate diagnosis is expert physician’s 
clinical judgment [26], but relatively few clinicians have a special interest in hyponatremia so this may 
not be practical. Moreover, a clinical history may be difficult to obtain due to cognitive or sensory 
impairment and multiple potential causes for hyponatremia may co-exist. Diagnosis of underlying 
causes depends crucially on accurate assessment of volemic status. However, there is currently no 
reliable biomarker of hydration for older people [27] and clinical examination is unreliable [27,28]. 
Accurate appreciation of the etiology of hyponatremia is essential, not only for appropriate clinical 
management but also to prevent development of hyponatremia. At present, there are few quality studies 
reporting etiology of hyponatremia in older people. Most reports are from retrospective studies that 
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rely on diagnosis made by non-expert clinicians retrospectively reviewing case notes, which frequently 
lack sufficient detail to allow accurate diagnosis (i.e., documentation of volemic status, appropriate 
investigations). The reported commonest cause of hyponatremia is SIADH [29]. However, with the 
increased prevalence of hyponatremia in older people there is no corresponding increased prevalence 
of SIADH [30]. This raises concern that SIADH may be over diagnosed, particularly in hypovolemic 
older people. Diagnosis of SIADH requires strict diagnostic criteria (e.g., urine concentration and 
sodium measurements). These important investigations are commonly neglected in routine clinical 
practice and so relevant data are frequently unavailable in observational studies. Moreover, the diagnosis 
of SIADH depends crucially on patients being in a euvolemic state which cannot be confirmed in the 
absence of a reliable biomarker of hydration for older people. One study reported that of all the cases 
of hyponatremia attributed to SIADH, not one fulfilled the SIADH diagnostic criteria [31]. Another 
group reported that specific etiology of SIADH was identifiable in only 54% of cases of hyponatremia 
ascribed to SIADH [32]. Whilst many cases of SIADH have no obvious cause, this raises the possibility 
that some are misdiagnosed. Subsequently patients may be subject to serious clinical consequences as 
the management of SIADH (fluid restriction) is the exact opposite of the management of hypovolemic 
hyponatremia (vigorous fluid replacement). 
Table 2. Main contributory causes of hyponatremia in older people [5]. 
Hypovolemic hyponatremia 
Inadequate fluid intake or replacement 
Diuretic therapy 
Diarrhea and vomiting 
Pancreatitis/third space loss of fluids 
Renal salt wasting 
Burns and skin losses 
Mineralocorticoid deficiency 
Euvolemic hyponatremia 
Syndrome of inappropriate antidiuretic hormone 
Medications 
Hypothyroidism 
Fluid loss with inappropriate fluid (salt) replacement 
Glucocorticoid deficiency 
Hypervolemic hyponatremia 
Cardiac failure 
Cirrhosis 
Chronic kidney disease 
Acute kidney injury 
Nephrotic syndrome 
Supporting the concerns of “inappropriate SIADH diagnoses”, three independent groups have found 
that the etiology of hyponatremia in older people is predominantly multifactorial, with patients 
presenting with conflicting signs of hydration [31–33]. This further complicates the already challenging 
task of diagnosing underlying causes of hyponatremia and reinforces the need for a reliable biomarker 
of hydration in older people [28]. 
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Further investigation of the elderly hyponatremic patient depends on the working diagnosis and 
readers may find it helpful to refer to recent open-access guidelines, which include a proposed 
algorithm [11]. However, these are not designed with frail elderly people in mind. For example, 
although urinalysis is recommended, the guidelines point out results may be misleading in those with 
chronic kidney disease or diuretics, both of which are highly prevalent in older age groups. 
Reportedly common underlying causes of hyponatremia include pharmacotherapies (thiazide  
and loop diuretics, antidepressants, anticonvulsants, non-steroidal anti-inflammatories, proton pump 
inhibitors), co-morbidities (congestive cardiac failure, renal failure, cirrhosis, respiratory infections), 
fluid overload and volume depletion [7,31–34]. Reports of the pharmacotherapy and polypharmacy 
associated hyponatremia are increasing. Thiazide diuretic induced hyponatremia has been described  
as a “silent epidemic” due largely to the combination of their prescription, degenerate renal physiology 
and concomitant prescription of non-steroidal anti-inflammatories [35]. This is important because  
of the high prevalence of hypertension in the aging population and widespread thiazide diuretic use. 
Similarly, the frequent prescribing pattern of other medications known to cause hyponatremia may be 
important contributing and easily treatable causes of the increased prevalence of hyponatremia in older 
people. Acknowledging the prevalence of polypharmacy in older patients Movig et al. [36] report that 
concomitant diuretic and selective serotonin reuptake inhibitor (SSRI) therapy incurs a 13.5 increased 
odds ratio of developing hyponatremia compared to SSRI therapy alone. Conversely, given the high 
prevalence of multiple co-morbidities and polypharmacy in older people it is likely that causes of 
hyponatremia attributable to simple hypovolemia are misattributed to other causes [31,33]. Hypovolemia 
may be the result of over use or incorrect use of diuretics, or inadequate fluid intake or replacement, or 
a combination of these, which may simply be overlooked in the presence of other potential contributing 
factors. These etiological reports are promising and suggest that the prevalence of hyponatremia  
in older people could potentially be reduced by appropriate prescribing patterns, optimization of  
co-morbidities and adequate fluid therapies. However, in most of these observational studies some 
important study design limitations should be considered. Frequent omission of appropriate clinical 
investigations, lack of documentation and/or questionable accuracy of records of volemic state and 
experience of the diagnosing clinicians may hinder results and cause erroneous diagnosis. These 
limitations notably reflect how challenging and neglected hyponatremia in elderly patients is in routine 
clinical practice. 
Further research is required to accurately delineate the cause(s) of hyponatremia in older people. 
Future studies should be prospective and include expert panel review, with completion and full data 
availability of appropriate investigations. In the meantime establishing a reliable biomarker of hydration 
for older people is necessary in order to increase accuracy of the diagnostic process. Accurate 
understanding of etiology of hyponatremia in older people may help prevent and improve clinical 
management of hyponatremia which could potentially deliver significant health and economic benefits 
in the form of reduced complications of hyponatremia. 
6. Treatment of Hyponatremia in Older People 
Treatment will depend on the underlying cause, although a recent review article highlighted 
significant differences in expert panel consensus recommendations for treatment of hyponatremia [37]. 
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Investigation of underlying cause will be the same as younger adults though special attention should  
be placed upon the possibility of medication-induced hyponatremia and volemic status. Sometimes,  
the treatment options are obvious, e.g., when hyponatremia is due to hypothyroidism or adrenal 
insufficiency. The high prevalence of multiple prescribed medications (polypharmacy) means many 
cases may be related to medications. Hypovolemic hyponatremia is especially common as fluid intake 
may be impaired by physical and cognitive function and decreased sensitivity of normal physiological 
thirst and homeostatic mechanisms [5]. Table 3 lists common treatment strategies and a brief synopsis 
of special considerations in older people. 
Table 3. Treatment options for hyponatremia. 
Treatment Indication Special Considerations in Older People 
Optimize prescribing Drug-induced hyponatremia 
Medications more likely to be needed due to  
co-morbidities. 
Isotonic saline Hypovolemic hyponatremia 
Hypovolemia common due to immobility, confusion 
and malnutrition. Assessment of volemic state is 
notoriously difficult so may worsen hyponatremia if 
underlying causes are misdiagnosed. 
Hypertonic saline 
Severe hyponatremia from 
any cause 
Needs expert monitoring. High potential for  
over-correction. 
Fluid restriction SIADH 
Poor tolerability and high failure rate. Will worsen 
hyponatremia where dehydration is misdiagnosed  
as SIADH. 
Demeclocycline SIADH 
Unpredictability of effect requires special caution 
due to lower resilience. 
Diuretics Hypervolemic hyponatremia 
Can worsen hyponatremia by increasing urinary 
sodium excretion. 
Salt tablets Hypovolemic hyponatremia 
Rarely indicated as dietary sodium intake is usually 
sufficient and total body sodium is not normally low 
in most cases of hyponatremia. 
Lithium SIADH 
Inconsistent results, with high risk of adverse drug 
effects and toxicity.  
Urea SIADH 
Only available in some countries. Unpalatable. 
Higher risk of uremia. 
Vaptans SIADH or hypervolemia 
Risk of dehydration and over-correction. Expensive. 
Only licensed for SIADH in Europe. 
6.1. Optimizing Prescribing 
Judicious use of medications and optimal drug prescribing is one of the cornerstones of comprehensive 
geriatric assessment [38]. Almost three-quarters of elderly patients with hyponatremia after fragility 
fracture were prescribed at least one medication known to cause hyponatremia [33]. Identification  
of the culprit medication and de-prescribing or minimizing the dose may be all that is required. As 
highlighted earlier, common medications implicated in elderly patients include thiazide diuretics and 
antidepressants. A high prevalence of proton pump inhibitor prescribing has been described in two 
recent and independent studies of older people with fragility fractures and hyponatremia [33,39]. It is 
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not known if stopping these agents can effectively prevent or treat hyponatremia, but this should be 
carefully considered because they are arguably over-used. Almost two-thirds of hospitalized older 
people prescribed proton pump inhibitors do not have a valid indication for their use [40]. 
6.2. Fluid Therapy or Restriction 
Since hyponatremia is usually a disorder of fluid balance rather than pure salt depletion, correction 
of volemic status is a mainstay of treatment. Fluid restriction, typically to about 800 mLs in 24 h, has 
long been the first line treatment of SIADH. It may be more acceptable in older people than younger 
patients but is often ineffective or poorly tolerated nevertheless. It can take a long time to be effective 
and is prone to failure due to hidden liquids in foods and discomfort from thirst. Moreover, in SIADH, 
there is a downward re-setting of the “thirst osmostat” and a lower plasma osmolality than normal will 
trigger thirst and increased fluid intake [41]. 
Intravenous fluid resuscitation is indicated in all forms of hypovolemic hyponatremia. In hypovolemic 
hyponatremia, isotonic saline suffices and will often lead to very rapid sodium increase, as non-osmotic 
vasopressin secretion is rapidly suppressed. Most experts recommend using only isotonic saline (0.9% 
solution of sodium chloride), but boluses of hypertonic solutions are often used in acute and/or severe 
hyponatremia. No more than 100 mLs of 3% saline are recommended, though these can be repeated as 
needed [26]. The latter requires intensive monitoring as there is a risk of osmotic demyelination  
with excessively rapid correction. Corrections below 4 mmol/L in 24 h are associated with poorer 
outcome [42] but the maximum rate of correction is more controversial with limits falling from 10 mmol/L 
in 24 h and 18 mmol/L in 48 h in 2007 [43] to just 6 mmol/L in 24 h in 2013 [26]. Two-hourly checks 
of serum sodium are recommended to optimize rate of correction [44] with re-lowering of sodium if 
there is excessively rapid correction in groups at risk of osmotic demyelination [26]. In older people, 
special caution should be taken to avoid over-hydration due to higher incidence of cardiac failure, 
lower glomerular filtration rate, decreased ability to concentrate urine and higher levels of arginine 
vasopressin than younger people. 
6.3. Vaptans 
The development of oral vasopressin receptor antagonists (vaptans) represents a major breakthrough 
in the treatment of SIADH and, potentially, other forms of euvolemic or hypervolemic hyponatremia. 
Unlike other treatments used for SIADH (see Table 3), the vaptans target the chief pathological 
mechanism that accounts for the hyponatremia in this condition, an inappropriately high level of 
arginine vasopressin resulting in dilutional hyponatremia. Tolvaptan was first shown to be superior to 
placebo in two randomized controlled trials that included hyponatremic patients aged up to 100 years 
old with SIADH, heart failure or cirrhosis (SALT-1 and SALT-2) [45]. It was also more effective than 
fluid restriction at normalizing serum sodium in one small, randomized trial [46]. Serum sodium tends 
to fall again on discontinuation so that treatment may have to be life-long in many cases [45,47]. 
However, tolvaptan was not significantly better than placebo at improving mortality in the EVEREST 
study of patients with chronic heart failure [48] but only 10% were hyponatremic at entry. In the  
sub-group with hyponatremia, those given tolvaptan were more than twice as likely to experience 
normalization of serums sodium and reported less breathlessness [49]. More recently, tolvaptan has 
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proven superior to placebo at raising sodium levels in SIADH in a Chinese population [50] and 
patients with cancer [51]. However, there remains a lack of convincing evidence of the effect on 
“hard” end-points such as decreased mortality or outcomes that older people value the most such as 
improved quality of life and better physical function [52]. A further concern is the high expense of the 
agents. However, one analysis of the SALT-1 and 2 suggests the reduction in length of stay in hospital 
is such that tolvaptan may be cost-effective [53]. 
6.4. Are Vaptans Safe in Old Age? 
A major concern in treatment of older people with any new agent is the safety profile. Preclinical 
data give some cause for concern as these are such powerful aquaretic agents, e.g., the diuresis 
observed in early studies of tolvaptan averaged over 5 liters per day [54]. Nevertheless, the prevalence 
of serious adverse effects after treatment with tolvaptan was similar to that seen with placebo in the 
SALT trials [45]. Common adverse effects in the first month of therapy included thirst (14%), dry 
mouth (13%), weakness (9%), constipation (9%) and nausea (8%). Tolvaptan also demonstrated a 
good safety profile after a median 9.9 months of treatment in the EVEREST study [48], though this  
has to be interpreted with caution as only 10% of participants had hyponatremia. Its long-term safety 
profile in the setting of hyponatremia was assessed in an open-label extension of the SALT trials called 
SALTWATER [47]. Only 6 out of 111 patients in the study had to discontinue treatment due to 
probable adverse drug reactions. Subsequent studies also report a good safety profile, though follow-up 
was short [49,51]. However, it remains uncertain if tolvaptan would be as well tolerated in frail, elderly 
individuals, particularly given the potential for inappropriate prescription in dehydrated patients  
mis-diagnosed with SIADH. Despite the laudable inclusion of extremely elderly individuals in the 
SALT trials of tolvaptan (the oldest volunteer was 100 years old), mean ages of participants were just 
60 years in SALT-1, 62 years in SALT-2 and 65 years in SALTWATER. The tolerability in the age 
group with arguably the most to gain from this treatment is therefore still unclear and warrants further 
evaluation in randomised controlled trials with more numerous older patients. 
Overall, the vaptans currently have a role where simple and less expensive measures have failed. 
Yet, the potential for their use in very elderly people might be under-estimated [25], because hyponatremia 
is much more common in this age group, the clinical implications of any improvements in postural 
balance and cognition will be much greater than in a younger population, the economic burden of 
uncorrected hyponatremia on falls [55] and cognitive impairment [56] is huge, and the shortened life 
expectancy of older people with hyponatremia may make the prospect of potentially life-long treatment 
more acceptable to healthcare funders [25]. It remains to be seen if vaptan therapy in older patient is 
safe and cost-effective. 
7. Conclusions 
Hyponatremia is especially common in frail older patient groups. Even mild, chronic hyponatremia 
is associated with increased cognitive impairment, falls and fractures, possibly via a decrease in  
bone mineral density and/or bone quality. There is some evidence to show treatment of hyponatremia 
improves cognitive performance and postural stability. Therefore, correction of hyponatremia seems 
sensible in groups at high risk of falls, immobility or loss of independence from cognitive impairment. 
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However, accurately diagnosing the causes of hyponatremia in this group is especially challenging, as 
hyponatremia may be multi-factorial, history hard to obtain due to cognitive or sensory impairment, 
and examination to determine volemic status is unreliable. Successful treatment also comes with  
its own challenges, both due to the potential for mis-diagnosis of underlying cause(s) and because all 
current therapies carry their own risks. Oral vasopressin receptor antagonists may be very helpful in 
this patient group, but the evidence base for their safety and efficacy on important outcomes in frail 
elderly groups is limited. 
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